Approach to the evaluation of the GH/IGF-axis in patients with pituitary disease: Which test to order

Pituitary

Volumn 10, Issue 2, 2007, Pages 205-211

  Roberts, Brian ^a   Katznelson, Laurence ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acromegaly; Growth hormone; Growth hormone deficiency; Insulin like growth factor 1; Pituitary

Indexed keywords

ARGININE; GLUCOSE; GONADORELIN; GROWTH HORMONE; HYDROCORTISONE; LEVOTHYROXINE; PROLACTIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; TESTOSTERONE; THYROXINE;

ACROMEGALY; ADRENAL INSUFFICIENCY; ADULT; ARTICLE; CASE REPORT; CAVERNOUS SINUS; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MONITORING; FEMALE; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE SECRETING ADENOMA; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOPHYSIS ADENOMA; HYPOPHYSIS DISEASE; HYPOTHYROIDISM; LEG EDEMA; LIFE EXPECTANCY; MALE; MENSTRUAL IRREGULARITY; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL EXAMINATION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROVOCATION TEST; SLEEP APNEA SYNDROME; THYROXINE BLOOD LEVEL; TRANSSPHENOIDAL HYPOPHYSECTOMY;

ACROMEGALY; ADULT; DIAGNOSTIC TECHNIQUES, ENDOCRINE; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED;

EID: 34249891075     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0026-x     Document Type: Article

References (40)

1. Orme SM, McNally RJ, Cartwright RA, Belchetz PE (1998) Mortality and cancer incidence in acromegaly: A retrospective cohort study. United Kingdom acromegaly study group. J Clin Endocrinol Metab 83:2730-2734
2. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B (1988) Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223:327-335
3. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95-102
4. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667-674
5. Swearingen B, Barker FG II, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
6. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: A consensus statement. J Clin Endocrinol Metab 85:526-529
7. Cook D, Ezzat S, Katznelson K, Kleinberg DL, Laws ER, Nippoldt TB, Swearingen B, Vance ML (2004) AACE medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract 10:213-225
8. Freda PU, Post KD, Powell JS, Wardlaw SL (1998) Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 83:3808-3816
9. Growth Hormone Research Society (2004) Biochemical assessment and long-term monitoring in patients with acromegaly: Statement from a joint conference of the growth hormone research society and the pituitary society. J Clin Endocrinol Metab 89:3099-3102
10. Duncan E, Wass JA (1999) Investigation protocol: Acromegaly and its investigation. Clin Endocrinol (Oxf) 50:285-293
11. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL (2002) Acromegaly with apparently normal GH secretion: Implications for diagnosis and follow-up. J Clin Endocrinol Metab 87:3537-3542
12. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE (1979) Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 301:1138-1142
13. Grinspoon S, Clemmons D, Swearingen B, Klibanski A (1995) Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. J Clin Endocrinol Metab 80:927-932
14. Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW (2003) Long-term treatment outcome in acromegaly. Growth Horm IGF Res 13:185-192
15. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results. J Clin Endocrinol Metab 83:3411-3418
16. Puder JJ, Nilavar S, Post KD, Freda PU (2005) Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab 90:1972-1978
17. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
18. de Boer H, Blok GJ, Van der Veen EA Clinical aspects of growth hormone deficiency in adults. Endocr Rev 16:63-86
19. Svensson J, Bengtsson BA, Rosen T, Oden A, Johannsson G (2004) Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 89:3306-3312
20. Corpas E, Harman SM, Blackman MR (1993) Human growth hormone and human aging. Endocr Rev 14:20-39
21. Weltman A, Weltman JY, Hartman ML, Abbott RD, Rogol AD, Evans WS, Veldhuis JD (1994) Relationship between age, percentage body fat, fitness, and 24-hour growth hormone release in healthy young adults: effects of gender. J Clin Endocrinol Metab 78:543-548
22. Growth Hormone Research Society (1998) Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 83:379-381
23. Gharib H, Cook DM, Saenger PH, Bengtsson BA, Feld S, Nippoldt TB, Rodbard HW, Seibel JA, Vance ML, Zimmerman D, Palumbo PJ, Bergman DA, Garber JR, Hamilton CR Jr, Petak SM, Rettinger HI, Service FJ, Shankar TP, Stoffer SS, Tourletot JB (2003) American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children - 2003 update. Endocr Pract 9:64-76
24. Biller BM, Samuels MH, Zagar A, Cook DM, Arafah BM, Bonert V, Stavrou S, Kleinberg DL, Chipman JJ, Hartman ML (2002) Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab 87:2067-2079
25. Aimaretti G, Corneli G, Razzore P, Bellone S, Baffoni C, Arvat E, Camanni F, Ghigo E (1998) Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab 83:1615-1618
26. Aimaretti G, Corneli G, Razzore P, Bellone S, Baffoni C, Bellone J, Camanni F, Ghigo E (1998) Usefulness of IGF-I assay for the diagnosis of GH deficiency in adults. J Endocrinol Invest 21:506-511
27. Span JP, Pieters GF, Sweep CG, Swinkels LM, Smals AG (1999) Plasma IGF-I is a useful marker of growth hormone deficiency in adults. J Endocrinol Invest 22:446-450
28. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ (2002) Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 87:477-485
29. Marzullo P, Di Somma C, Pratt KL, Khosravi J, Diamandis A, Lombardi G, Colao A, Rosenfeld RG (2001) Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 86:3001-3008
30. Granada ML, Murillo J, Lucas A, Salinas I, Llopis MA, Castells I, Foz M, Sanmarti A (2000) Diagnostic efficiency of serum IGF-I, IGF-binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and urinary GH measurements in the diagnosis of adult GH deficiency: Importance of an appropriate reference population. Eur J Endocrinol 142:243-253
31. Hasegawa Y, Hasegawa T, Aso T, Kotoh S, Tsuchiya Y, Nose O, Ohyama Y, Araki K, Tanaka T, Saisyo S et al (1993) Comparison between insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) measurement in the diagnosis of growth hormone deficiency. Endocr J 40:185-190
32. Abs R (2003) Update on the diagnosis of GH deficiency in adults. Eur J Endocrinol 148(2):S3-S8
33. Abs R, Bengtsson BA, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P, Wuster C (1999) GH replacement in 1034 growth hormone deficient hypopituitary adults: Demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf) 50:703-713
34. Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P, Wuster C (1999) The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab 84:3929-3935
35. Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerblad M, Manhem P, Rosen T, Thoren M, Bengtsson BA (1996) The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. J Clin Endocrinol Metab 81:1575-1581
36. Chipman JJ, Attanasio AF, Birkett MA, Bates PC, Webb S, Lamberts SW (1997) The safety profile of GH replacement therapy in adults. Clin Endocrinol (Oxf) 46:473-481
37. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396
38. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625
39. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS (2000) Hormonal predictors of prostate cancer: A meta-analysis. J Clin Oncol 18:847-853
40. Monson JP (2003) Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 148(2):S9-S14